NDANASALSPRAY, METERED
Approved
Jun 2021
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASTEPRO ALLERGY is an azelastine hydrochloride nasal spray approved in June 2021 for allergic rhinitis and vasomotor rhinitis. It is a selective histamine H1 receptor antagonist delivered via intranasal metered spray that provides rapid local anti-inflammatory relief in the nasal cavity.
LOE Approaching2.1 years to LOE
Product is 2.1 years from loss of exclusivity with modest competitive pressure (15 competitors), indicating a transition phase where defensive strategies and transition planning will intensify.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis
Started Mar 2011
347 enrolled
Perennial Allergic Rhinitis
Why This Matters for Your Career
Worked on ASTEPRO ALLERGY at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.